Inhibiting endocannabinoid biosynthesis: A novel approach to the treatment of constipation

British Journal of Pharmacology

Volumn 172, Issue 12, 2015, Pages 3099-3111

  Bashashati, M ^a   Nasser, Y ^b   Keenan, C M ^a   Ho, W ^a   Piscitelli, F ^c   Nalli, M ^d   Mackie, K ^e   Storr, M A ^b,f   Di Marzo, V ^c   Sharkey, K A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c CNR   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e INDIANA UNIVERSITY   (United States)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; DIACYLGLYCEROL LIPASE ALPHA; DIACYLGLYCEROL LIPASE BETA; DIGESTIVE TRACT AGENT; ENDOCANNABINOID; LIPOPROTEIN LIPASE; OMDM 188; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; ACYLGLYCEROL; ARACHIDONIC ACID DERIVATIVE; CANNABINOID 1 RECEPTOR; GLYCERYL 2-ARACHIDONATE; ISOLEUCINE; LACTONE; N-FORMYL-ISOLEUCINE-1-((3-HEXYL-4-OXO-2-OXETANYL)METHYL)DODECYL ESTER; SCOPOLAMINE BROMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CONSTIPATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME LOCALIZATION; FECES ANALYSIS; GASTROINTESTINAL MOTILITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE CONTRACTION; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C3H MOUSE; C57BL MOUSE; DRUG EFFECTS; GENETICS; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ARACHIDONIC ACIDS; CONSTIPATION; ENDOCANNABINOIDS; GASTROINTESTINAL MOTILITY; GLYCERIDES; ISOLEUCINE; LACTONES; LIPOPROTEIN LIPASE; MALE; MASS SPECTROMETRY; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; RECEPTOR, CANNABINOID, CB1; SCOPOLAMINE HYDROBROMIDE;

EID: 84930196343     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13114     Document Type: Article

References (63)

1. Abalo R, Vera G, Lõpez-Pérez AE, Martinez-Villaluenga M, Martín-Fontelles MI, (2012). The gastrointestinal pharmacology of cannabinoids: focus on motility. Pharmacology 90: 1-10.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Ion Channels. Br J Pharmacol 170: 1607-1651.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013d). The Concise Guide to PHARMACOLOGY 2013/14: Transporters. Br J Pharmacol 170: 1706-1796.
6. Alger BE, Kim J, (2011). Supply and demand for endocannabinoids. Trends Neurosci 34: 304-315.
7. Alhouayek M, Muccioli GG, (2012). The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends Mol Med 18: 615-625.
8. Alhouayek M, Lambert DM, Delzenne NM, Cani PD, Muccioli GG, (2011). Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. FASEB J 25: 2711-2721.
9. Anitha M, Vijay-Kumar M, Sitaraman SV, Gewirtz AT, Srinivasan S, (2012). Gut microbial products regulate murine gastrointestinal motility via toll-like receptor 4 signaling. Gastroenterology 143: 1006-1016.
10. Baggelaar MP, Janssen FJ, van Esbroeck AC, den Dulk H, Allarà M, Hoogendoorn S, et al. (2013). Development of an activity-based probe and in silico design reveal highly selective inhibitors for diacylglycerol lipase-α in brain. Angew Chem Int Ed Engl 52: 12081-12085.
11. Bashashati M, Storr MA, Nikas SP, Wood JT, Godlewski G, Liu J, et al. (2012). Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice. Br J Pharmacol 165: 1556-1571.
12. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, et al. (2003). Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163: 463-468.
13. Bisogno T, Burston JJ, Rai R, Allarà M, Saha B, Mahadevan A, et al. (2009). Synthesis and pharmacological activity of a potent inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol. ChemMedChem 4: 946-950.
14. Bisogno T, Mahadevan A, Coccurello R, Chang JW, Allarà M, Chen Y, et al. (2013). A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol with potential anti-obesity effects. Br J Pharmacol 169: 784-793.
15. Blankman JL, Cravatt BF, (2013). Chemical probes of endocannabinoid metabolism. Pharmacol Rev 65: 849-871.
16. Camilleri M, Carlson P, McKinzie S, Grudell A, Busciglio I, Burton D, et al. (2008). Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation. Am J Physiol Gastrointest Liver Physiol 294: G13-G19.
17. Capasso R, Matias I, Lutz B, Borrelli F, Capasso F, Marsicano G, et al. (2005). Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology 129: 941-951.
18. Cascio MG, (2013). PUFA-derived endocannabinoids: an overview. Proc Nutr Soc 72: 451-459.
19. Coutts AA, Irving AJ, Mackie K, Pertwee RG, Anavi-Goffer S, (2002). Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol 448: 410-422.
20. Di Marzo V, (2011). Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight. Nat Neurosci 14: 9-15.
21. Di Marzo V, Cristino L, (2008). Why endocannabinoids are not all alike. Nat Neurosci 11: 124-126.
22. Di Marzo V, De Petrocellis L, (2012). Why do cannabinoid receptors have more than one endogenous ligand? Philos Trans R Soc Lond B Biol Sci 367: 3216-3228.
23. Di Marzo V, Goparaju SK, Wang L, Liu J, Bátkai S, Járai Z, et al. (2001). Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410, 822-825.
24. Dinh TP, Freund TF, Piomelli D, (2002). A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 121: 149-158.
25. Duncan M, Thomas AD, Cluny NL, Patel A, Patel KD, Lutz B, et al. (2008). Distribution and function of monoacylglycerol lipase in the gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol 295: G1255-G1265.
26. Galve-Roperh I, Chiurchiu V, Díaz-Alonso J, Bari M, Guzman M, Maccarrone M, (2013). Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. Prog Lipid Res 52: 633-650.
27. Hons IM, Storr MA, Mackie K, Lutz B, Pittman QJ, Mawe GM, et al. (2012). Plasticity of mouse enteric synapses mediated through endocannabinoid and purinergic signaling. Neurogastroenterol Motil 24: e113-e124.
28. Howlett AC, (2002). The cannabinoid receptors. Prostaglandins Other Lipid Mediat 68-69: 619-631.
29. Hsu KL, Tsuboi K, Whitby LR, Speers AE, Pugh H, Inloes J, et al. (2013). Development and optimization of piperidyl-1,2,3-triazole ureas as selective chemical probes of endocannabinoid biosynthesis. J Med Chem 56: 8257-8269.
30. Iannotti FA, Piscatelli F, Martella A, Mazzarella E, Allara M, Palmieri V, et al. (2013). Analysis of the 'endocannabinoidome' in peripheral tissues of obese Zucker rats. Prostaglandins Leukot Essent Fatty Acids 89: 127-135.
31. Izzo AA, Camilleri M, (2008). Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 57: 1140-1155.
32. Izzo AA, Sharkey KA, (2010). Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 126: 21-38.
33. Izzo AA, Fezza F, Capasso R, Bisogno T, Pinto L, Iuvone T, et al. (2001). Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 134: 563-570.
34. Jain T, Wager-Miller J, Mackie K, Straiker A, (2013). Diacylglycerol lipaseα (DAGLα) and DAGLβ cooperatively regulate the production of 2-arachidonoyl glycerol in autaptic hippocampal neurons. Mol Pharmacol 84: 296-302.
35. Kachur JF, Morgan DW, Gaginella TS, (1986). Effect of dextromethorphan on guinea pig ileal contractility in vitro: comparison with levomethorphan, loperamide and codeine. J Pharmacol Exp Ther 239: 661-667.
36. Kasparek MS, Linden DR, Kreis ME, Sarr MG, (2008). Gasotransmitters in the gastrointestinal tract. Surgery 143: 455-459.
37. Katona I, Urban GM, Wallace M, Ledent C, Jung KM, Piomelli D, et al. (2006). Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci 26: 5628-5637.
38. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
39. Kinsey SG, Wise LE, Ramesh D, Abdullah R, Selley DE, Cravatt BF, et al. (2013). Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects. J Pharmacol Exp Ther 345: 492-501.
40. Krueger D, Michel K, Allam S, Weiser T, Demir IE, Ceyhan GO, et al. (2013). Effect of hyoscine butylbromide (Buscopan®) on cholinergic pathways in the human intestine. Neurogastroenterol Motil 25: e530-e539.
41. Kunze WA, Furness JB, (1999). The enteric nervous system and regulation of intestinal motility. Annu Rev Physiol 61: 117-142.
42. Maccarrone M, Rossi S, Bari M, De Chiara V, Fezza F, Musella A, et al. (2008). Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci 11: 152-159.
43. MacNaughton WK, Van Sickle MD, Keenan CM, Cushing K, Mackie K, Sharkey KA, (2004). Distribution and function of the cannabinoid-1 receptor in the modulation of ion transport in the guinea pig ileum: relationship to capsaicin-sensitive nerves. Am J Physiol Gastrointest Liver Physiol 286: G863-G871.
44. Marquez L, Suarez J, Iglesias M, Bermudez-Silva FJ, Rodriguez de Fonseca F, Andreu M, (2009). Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS ONE 4: e6893.
45. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
46. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83-90.
47. Min R, Testa-Silva G, Heistek TS, Canto CB, Lodder JC, Bisogno T, et al. (2010). Diacylglycerol lipase is not involved in depolarization-induced suppression of inhibition at unitary inhibitory connections in mouse hippocampus. J Neurosci 30: 2710-2715.
48. Muccioli GG, (2010). Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discov Today 15: 474-483.
49. Murataeva N, Straiker A, Mackie K, (2014). Parsing the players: 2-arachidonoylglycerol synthesis and degradation in the CNS. Br J Pharmacol 171: 1379-1391.
50. Ortar G, Bisogno T, Ligresti A, Morera E, Nalli M, Di Marzo V, (2008). Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem 51: 6970-6979.
51. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucleic Acids Res 42 (Database Issue): D1098-D1106.
52. Pertwee RG, (2001). Cannabinoids and the gastrointestinal tract. Gut 48: 859-867.
53. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol Rev 62: 588-631.
54. Pinto L, Izzo AA, Cascio MG, Bisogno T, Hospodar-Scott K, Brown DR, et al. (2002). Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 123: 227-234.
55. Piomelli D, (2003). The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4: 873-884.
56. Ramesh D, Ross GR, Schlosburg JE, Owens RA, Abdullah RA, Kinsey SG, et al. (2011). Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice. J Pharmacol Exp Ther 339: 173-185.
57. Storr MA, Bashashati M, Hirota C, Vemuri VK, Keenan CM, Duncan M, et al. (2010). Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice. Neurogastroenterol Motil 22: 787-796, e223.
58. Ueda N, Tsuboi K, Uyama T, (2010). Enzymological studies on the biosynthesis of N-acylethanolamines. Biochim Biophys Acta 1801: 1274-1285.
59. Ueda N, Tsuboi K, Uyama T, Ohnishi T, (2011). Biosynthesis and degradation of the endocannabinoid 2-arachidonoylglycerol. Biofactors 37: 1-7.
60. Wong BS, Camilleri M, Busciglio I, Carlson P, Szarka LA, Burton D, et al. (2011). Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology 141: 1638-1647.
61. Wood JT, Williams JS, Pandarinathan L, Janero DR, Lammi-Keefe CJ, Makriyannis A, (2010). Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma. J Lipid Res 51: 1416-1423.
62. Yoshino H, Miyamae T, Hansen G, Zambrowicz B, Flynn M, Pedicord D, et al. (2011). Postsynaptic diacylglycerol lipase mediates retrograde endocannabinoid suppression of inhibition in mouse prefrontal cortex. J Physiol 589: 4857-4884.
63. Zhang L, Wang M, Bisogno T, Di Marzo V, Alger BE, (2011). Endocannabinoids generated by Ca2+ or by metabotropic glutamate receptors appear to arise from different pools of diacylglycerol lipase. PLoS ONE 6: e16305.